Since all upstream Hippo pathway regulators converge upon YAP nuclear localization and transcriptional responses, pharmacological inhibition of YAP activity represents an effective anticancer strategy against human cancers caused by abnormal Hippo signaling. The gene discussed is YAP1; the disease is cancer.